SlideShare a Scribd company logo
Huateng Pharma https://en.huatengsci.com
What Are The World's Top Selling
Drugs?
After reviewing the top 10 oncology pharmaceutical companies 2020, now let's
find the top 10 best-selling drugs in the world of 2020.
Top 10 Best-selling Drugs of
2020
 1. Humira (AbbVie) — $20.39 billion
 2. Keytruda (Merck & Co.) — $14.38 billion
 3. Revlimid (Bristol Myers Squibb) — $12.15 billion
 4. Eliquis (Bristol Myers Squibb and Pfizer ) — $9.17 billion
 5. Imbruvica (AbbVie, Johnson & Johnson) — $8.43 billion
 6. Eylea (Regeneron Pharmaceuticals, Bayer) — $8.36 billion
 7. Stelara (Janssen )—$7.94 billion
 8. Opdivo (Bristol Myers Squibb, Ono Pharmaceutical) — $7.92 billion
 9. Biktarvy (Gilead) —$7.26 billion
 ​ 10. Xarelto (Bayer ) — $6.93 billion
​
Huateng Pharma https://en.huatengsci.com
1. Humira (Adalimumab)
Company: AbbVie
Mechanism of action: TNFα inhibitor
Approved indications: rheumatoid arthritis, polyarticular juvenile idiopathic
arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, hidradenitis
suppurativa, ulcerative colitis, plaque psoriasis
Sales in 2020: $20.39 billion
Adalimumab has a 3.5% global growth in 2020 after experiencing a decline in
sales of up to 3.9% in 2019.
Adalimumab faced competition from European biosimilars for the first time in
2019, when its international sales declined by up to 31%. However, during the
COVID-19 epidemic in 2020, adalimumab sales increased every quarter, from
$4.77 billion in the first quarter to $5.15 billion in the fourth quarter, due to the
inconvenience of patients visiting hospitals and the tendency to maintain their
original treatment.
Adalimumab will remain at the head of the immune field for the next few years,
with its biggest rival being Johnson & Johnson's Stelara, which generated sales
of $7.71 billion last year. The U.S. biosimilar market is also seeing increased
competition as adalimumab's patent expiration date approaches in 2023.
Adalimumab has remained the world's best-selling drug since 2012, and if it
remains at the top in 2021, it will surpass Lipitor as the world's best-selling drug
of all time.
2. Keytruda (Pembrolizumab)
Company: Merck & Co.
Mechanism of action: PD-1 blocker
Approved indications: melanoma, non-small cell lung cancer, small cell lung
cancer, head and neck cancer, Hodgkin lymphoma, large B-cell lymphoma,
bladder cancer, colorectal cancer, stomach cancer, esophageal cancer, cervical
cancer, liver cancer, Merkel cell carcinoma, kidney cancer (in combination with
Inlyta), endometrial cancer (in combination with Lenvima)
Sales in 2020: $14.38 billion
Merck seized the opportunity when immune targets became a direction of
treatment for cancer. Keytruda could claim the top spot by 2023 when AbbVie’s
Humira patent expires.
Huateng Pharma https://en.huatengsci.com
The immuno-oncology market is changing rapidly. Sales of Opdivo, also a PD-1
inhibitor, have been declining, while Keytruda has received seven FDA
approvals in the past 10 months.
Keytruda is an important advance in the treatment of advanced cancers with a
large number of genetic mutations, often in children with TMB-H cancers that
are difficult to cure. Keytruda has also received approval for relapsed or
metastatic squamous cell carcinoma of the skin that cannot be cured by surgery
or radiation therapy, and for the first-line treatment of patients with metastatic
or inoperable colorectal cancer with high microsatellite instability or mismatch
repair defects.
Keytruda is also approved for the treatment of Hodgkin's lymphoma and breast
cancer, as well as an approval last month for the treatment of patients with
locally advanced or metastatic esophageal or gastroesophageal junction cancer.
Merck continues its efforts to extend the drug's patent life through
co-formulations, combinations and alternate routes of administration.
3. Revlimid(Lenalidomide)
Company: Bristol Myers Squibb
Mechanism of action: IL6 inhibitor; CRBN inhibitor; COX-2 inhibitor; TNFα
inhibitor
Approved indications: Multiple myeloma, myelodysplastic syndromes,
mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma
Sales in 2020: $12.15 billion
Revlimid, approved by the FDA in 2005, had a down period after being acquired
in 2019, but last year it reached sales of more than $12 billion, jumping to the
top three drugs by annual sales. This was achieved with multiple price increases
for Revlimid. Celgene sold the drug initially for $215, but after 20 price
increases, it now costs more than $750. Celgene used these aggressive price
increases to reach its financial goals.
Both Celgene and BMS struggled to keep Revlimid safe from generic
competition. Shortly after the acquisition was completed, the U.S. Patent and
Trademark Office denied Revlimid's application to invalidate three patents. Last
year, however, BMS made concessions to allow Indian generic drug makers to
produce a limited number of generics after March 2022, and the three
drugmakers mentioned in the agreement signed by BMS can launch an
unlimited number of generics in 2026.
BMS was willing to free up the market for Revlimid generics as they had just
received two CAR-T approvals and they were in the early stages of the key
Huateng Pharma https://en.huatengsci.com
launch phases for anemia, multiple sclerosis and acute myeloid leukemia. BMS
was confident of future gains.
4. Eliquis (Apixaban)
Company: Bristol Myers Squibb and Pfizer
Mechanism of action: inhibitor of free and clot-bound factor Xa
Approved indications: Nonvalvular atrial fibrillation
Sales in 2020: $9.17 billion
Eliquis, jointly developed by Pfizer and BMS, was approved by the EMA in 2011
and by the FDA in 2012. Eliquis ranks as the fifth best-selling drug in the world
with annual sales of more than $9 billion in 2020.
Pfizer funds around half of the development costs, and the two companies share
profits and losses equally. In some countries, Pfizer sells the drug and pays BMS
a fee. Pfizer and BMS have changed dramatically in recent years as Eliquis sales
have soared. Pfizer moved both its generic and off-patent Upjohn businesses to
focus more on innovation and new drugs, and BMS acquired Celgene.
Prescriptions for oral anticoagulants show an overall downward trend during the
COVID-19 epidemic in 2020, with a rebound in volume by early 2021. Eliquis
sales jumped 37% to $2.6 billion in the first quarter as related studies showed
that blood thinners can boost the efficacy of COVID-19.
Eliquis sales increased 16% over 2019. Pfizer earned a total of $4.95 billion in
joint revenue with BMS and direct sales. The outlook for Eliquis is good as the
market expands further.
5. Imbruvica (Ibrutinib)
Company: AbbVie, Johnson & Johnson
Mechanism of action: BTK inhibitor
Approved indications: Mantle cell lymphoma, chronic lymphocytic leukemia,
Waldenstrom’s macroglobulinemia, marginal zone lymphoma, chronic graft vs.
host disease
Sales in 2020: $8.43 billion
Imbruvica is now one of the world's leading anti-blood cancer drugs, with sales
reaching $8.43 billion last year, demonstrating its dominance in the BTK
inhibitor market.
Huateng Pharma https://en.huatengsci.com
Imbruvica's 2020 sales are split between AbbVie ($5.31 billion) and Johnson &
Johnson ($4.13 billion). AbbVie's revenue includes $1.09 billion in collaboration
revenue.
Johnson & Johnson acquired 50% of Imbruvica for less than $1 billion in 2011,
and four years later Imbruvica's price skyrocketed due to AbbVie's $21 billion
acquisition of Pharmacyclics and a lone product. A year later, Imbruvica
received key approval as the first chemotherapy-free treatment for first-line
chronic lymphocytic leukemia patients. Since then, the therapy has received six
more approvals, the last three in combination with other drugs.
But like other drugs, Imbruvica faces challengers. The first is AstraZeneca's
Calquence, approved by the FDA in November 2019, with long-term data
published last year showing that treated patients with cytosolic lymphoma had
an average disease duration of 22 months without progression and a survival
rate of more than 50% after three years.
Another competitor is Brukinsa from BeiGene, which is only approved in the US
for condyloma lymphoma. The drug won the nod in China for recurrent SLL / CLL.
Late last year, BeiGene showed that for marginal zone lymphoma, Brukinsa
elicited responses in 74% of patients and completely eliminated the cancer in
24% within a year. The corresponding figures for Imbruvika were 48% and 5%,
respectively, although the trials did not compare the two drugs with each other.
To keep Imbruvica sales growing, AbbVie built a strong patent wall around it,
extending its exclusivity patent period by nine years, shielding it from biosimilar
competition and thus allowing prices to remain high and bring in more revenue.
6. Eylea (Aflibercept )
Company: Regeneron Pharmaceuticals, Bayer
Mechanism of action: PGF inhibitor, VEGFA inhibitor
Approved indications: wet age-related macular degeneration, diabetic
macular edema, diabetic retinopathy, macular edema
Sales in 2020: $8.36 billion
Eylea booked $8.36 billion in 2020 sales, split between $4.95 billion for
Regeneron in the U.S., and $2.82 billion for Bayer, which markets the macular
degeneration drug outside the U.S.
Due to the COVID-19 outbreak, new patients only got access to Eylea in late
March and early April, but the drug still performed better in the first quarter than
most of the year. In the second quarter, Eylea sales declined 4 percent but still
exceeded expectations, and by the fourth quarter, Eylea sales were up 10
percent and full-year sales were up 7 percent over 2019.
Huateng Pharma https://en.huatengsci.com
Eylea's competitor is Novartis' Beovu, however, last year it was reported that
Beovu may be linked to obstructive retinal vasculitis, which may lead to vision
loss. Regeneron and Bayer used this to promote Eylea's drug safety. In April
2020, the National Institutes of Health released data showing that Eylea
reduces the risk of developing vision-threatening complications by 68 percent.
But in the middle of last year, Novartis filed a lawsuit against Regeneron for
infringement of the pre-filled syringe technology, setting off an all-out patent
battle between Regeneron and Novartis in the ophthalmology field.
7. Stelara(Ustekinumab)
Company: Janssen
Mechanism of action: IL12 inhibitor, IL23 inhibitor
Approved indications: plaque psoriasis, psoriatic arthritis, Crohn's disease,
ulcerative colitis
Sales in 2020: $7.94 billion
Stelara's approval in ulcerative colitis has a strong impact on its sales growth in
2020. Meanwhile, the FDA's safety warning for Stelara's two JAK inhibitor
competitors (Xeljanz and Rinvoq) has also helped its market share capture.
Johnson & Johnson has cut the price of its IL-12 / 23 significantly to remain
competitive in light of growing competition. Despite this, Stelara achieved $7.94
billion in revenue last year, an increase of nearly 20% over 2019.
But Stelara also faces threats from the price side. One is from competing drugs,
and after Johnson & Johnson reported third-quarter results, it is considering
discounting and reducing prices on its products to secure market share. The
second is from government controls on drug prices, combined with high
unemployment and other effects, and price pressure could continue into 2021.
8. Opdivo (Nivolumab)
Company: Bristol Myers Squibb, Ono Pharmaceutical
Mechanism of action: PD-1 inhibitor
Approved indications: melanoma, non-small cell lung cancer, small cell lung
cancer, kidney cancer, Hodgkin Lymphoma, head and neck cancer, bladder
cancer, colorectal cancer, liver cancer
Sales in 2020: $7.92 billion
In terms of biopharmaceutical competition, a familiar fight is believed to be the
Keytruda-Opdivo battle, which is akin to Pepsi and Coke.
Huateng Pharma https://en.huatengsci.com
During the development process, they competed with each other as immune
checkpoint inhibitor rivals, and were approved by FDA successively in the same
year. Early on, Opdivo was in the lead, but later on, the development was quite
opposite. Keytruda sales grew 29% in 2020, while Opdivo's share continued to
shrink as Keytruda's market share continued to grow, but Opdivo's declined 2%.
And in each quarter of 2020 and the last quarter of 2019, Opdivo sales declined
compared to the same period last year.
Keytruda received 7 FDA approvals in 2019, but no gains for Opdivo. In
non-squamous non-small cell lung cancer, the combination therapy of Opdivo
with chemotherapy also did not show a significant improvement in efficacy over
chemotherapy alone.
But in 2020, Opdivo has received seven FDA approvals, two of which were in
combination with Bristol's CTLA4 immunotherapy Yervoy, for use in key NSCLC
areas. There have also been recent positive evaluations for gastric and
esophageal cancers. In addition, last October, Opdivo reported another NSCLC
win - a positive effect of Opdivo in combination with chemotherapy prior to
surgery, with Opdivo beating several competitors, including its dreaded
nemesis.
Opdivo was first shown to be effective in treating muscle-invasive bladder
cancer in a clinical trial in February of this year. This was followed by another
clinical success in April - patients with early-stage non-small cell lung cancer
who were treated with a combination of Opdivo and chemotherapy prior to
surgery were nearly 14 times more likely to have cancer-free tissue in their
resected tissue than patients treated with chemotherapy alone. This is a
milestone in the yet-to-be-realized adoption of Keytuda.
The competition among PD-1 inhibitors is being rekindled.
9. Biktarvy
Company: Gilead Sciences
Mechanism of action: HIV integrase inhibitor; RT inhibitor; HIV-1 RT inhibitor
Approved indications: HIV
Sales in 2020: $7.26 billion
Compared to 2019, Biktarvy's 2020 sales increase by 53%, jumping from the
17th to the 9th best-selling drug, far exceeding the original projected goal.
Although Biktarvy sales jumped $2.52 billion in 2020, a large portion of patients
using Biktarvy were originally using Gilead's other anti-HIV products, which had
a $1.93 billion sales decline. Overall, Gilead's HIV products generated sales of
$16.94 billion in 2020. Although this figure represents 69 percent of the
Huateng Pharma https://en.huatengsci.com
company's total revenue, Gilead's HIV drug revenue is up just 3 percent from
2019.
Biktarvy's competition doesn't just come from the inside of the company, such
as Descovy, which saw its sales in the U.S. jump from $1.08 billion in 2019 to
$1.53 billion last year.
Competition from outside the company is equally strong. GSK has been in the
HIV space for two decades, and its joint venture with Pfizer and Shionogi, ViiV
Healthcare, introduces strong challengers to the market every few years. ViiV is
pinning its latest hopes on Dovato, a two-drug combination with a better safety
profile that generated $374 million in sales in its first year of approval in 2019.
10. Xarelto (Rivaroxaban)
Company: Bayer
Mechanism of action: inhibitor of free and clot-bound factor Xa
Approved indications: Pulmonary embolism; Stroke; Venous thrombosis;
Embolism; Venous thromboembolism; Arterial atherosclerosis
Sales in 2020: $6.93 billion
In 2020, Xarelto's total revenue was about $6.93 billion, slightly more than its
$6.35 billion in 2019. Bayer received $4.58 billion of that amount, while Johnson
& Johnson received about $2.35 billion. 9% sales growth was not enough to gain
an edge against Pfizer and BMS' Eliquis, which had full-year sales of about $9.17
billion, and Eliquis continues to dominate the blood thinner segment.
The FDA approved Xarelto in October 2019 to help prevent blood clots in acutely
ill patients and without a high risk of bleeding during and after
hospitalization.The FDA's nod marks the sixth indication for Xarelto for blood
clots, while Eliquis is for the third indication. Last March, the American College of
Medicine (ACM) released data showing that the combination of Xarelto and
aspirin resulted in a 15% reduction in the risk of major limb and cardiovascular
events in patients with symptomatic peripheral arterial disease.
Reference:
https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales
As a reliable pharmaceutical intermediates supplier, Huateng Pharma is able to
provide the services of pharma intermediates's process development and
scale-up production with capacities varying from gram to kilograms and multi
tons. We have our own industrial park of 34,000 square meters that has been
completed and put into operation since 2020 to support multi tons production.
Huateng Pharma https://en.huatengsci.com
Related Articles:
The Rise of Antibody-Drug Conjugates (ADCs) - 'Guided-Missile' Cancer Drugs
New Drug Approvals & Upcoming FDA Approvals 2021
​ Top 8 Blockbuster Peptide Drugs
​ Top 10 Oncology Pharmaceutical Companies 2020​

More Related Content

What's hot

Recent updates in pharma bhavesh mor
Recent updates in pharma bhavesh morRecent updates in pharma bhavesh mor
Recent updates in pharma bhavesh mor
Bhavesh Mor
 
Biosimilars white paper asia pac 311012
Biosimilars white paper asia pac 311012Biosimilars white paper asia pac 311012
Biosimilars white paper asia pac 311012
QuintilesIMS Asia Pacific
 
The Era Of Generics By Shaji July 2009
The Era Of Generics   By Shaji July 2009The Era Of Generics   By Shaji July 2009
The Era Of Generics By Shaji July 2009
shajijohnvanilla
 
Biosimilars: A New Wave of Generic Drugs
Biosimilars: A New Wave of Generic DrugsBiosimilars: A New Wave of Generic Drugs
Biosimilars: A New Wave of Generic Drugs
indexcalculation
 
Swapnil2
Swapnil2Swapnil2
Swapnil2
swapy123
 
The new war on pharmaceutical drugs
The new war on pharmaceutical drugsThe new war on pharmaceutical drugs
The new war on pharmaceutical drugs
Duygu Can
 
Pfizer
PfizerPfizer
Pfizer
Kush Dua
 
Europe biosimilars market & pipeline insight
Europe biosimilars market & pipeline insightEurope biosimilars market & pipeline insight
Europe biosimilars market & pipeline insight
KuicK Research
 
Com^3.ppt
Com^3.pptCom^3.ppt
Com^3.ppt
Shubhda Roy
 
Opportunities and barriers in the biosimilar marketevolution or revolution fo...
Opportunities and barriers in the biosimilar marketevolution or revolution fo...Opportunities and barriers in the biosimilar marketevolution or revolution fo...
Opportunities and barriers in the biosimilar marketevolution or revolution fo...
Generic Pharma 2.0
 
GDHC118PIDR_Peripheral Artery Disease_sample
GDHC118PIDR_Peripheral Artery Disease_sampleGDHC118PIDR_Peripheral Artery Disease_sample
GDHC118PIDR_Peripheral Artery Disease_sample
Shaan Thakerar
 
Api china-2013
Api china-2013Api china-2013
Api china-2013
Arvindkumar S
 
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
Antonio Iervolino
 
2016-EDF-Pharma-Innovation
2016-EDF-Pharma-Innovation2016-EDF-Pharma-Innovation
2016-EDF-Pharma-Innovation
Antonio Iervolino
 
Patent cliff
Patent cliffPatent cliff
Patent cliff
PVR Prasad (Blue)
 
Presentation Assogenerici_Biosimilars_Iervolino IMS
Presentation Assogenerici_Biosimilars_Iervolino IMSPresentation Assogenerici_Biosimilars_Iervolino IMS
Presentation Assogenerici_Biosimilars_Iervolino IMS
Antonio Iervolino
 
‘Orphan drugs’ future growth potential for indian pharmaceutical market
‘Orphan drugs’ future growth potential for indian pharmaceutical market‘Orphan drugs’ future growth potential for indian pharmaceutical market
‘Orphan drugs’ future growth potential for indian pharmaceutical market
Nitin Patel
 

What's hot (17)

Recent updates in pharma bhavesh mor
Recent updates in pharma bhavesh morRecent updates in pharma bhavesh mor
Recent updates in pharma bhavesh mor
 
Biosimilars white paper asia pac 311012
Biosimilars white paper asia pac 311012Biosimilars white paper asia pac 311012
Biosimilars white paper asia pac 311012
 
The Era Of Generics By Shaji July 2009
The Era Of Generics   By Shaji July 2009The Era Of Generics   By Shaji July 2009
The Era Of Generics By Shaji July 2009
 
Biosimilars: A New Wave of Generic Drugs
Biosimilars: A New Wave of Generic DrugsBiosimilars: A New Wave of Generic Drugs
Biosimilars: A New Wave of Generic Drugs
 
Swapnil2
Swapnil2Swapnil2
Swapnil2
 
The new war on pharmaceutical drugs
The new war on pharmaceutical drugsThe new war on pharmaceutical drugs
The new war on pharmaceutical drugs
 
Pfizer
PfizerPfizer
Pfizer
 
Europe biosimilars market & pipeline insight
Europe biosimilars market & pipeline insightEurope biosimilars market & pipeline insight
Europe biosimilars market & pipeline insight
 
Com^3.ppt
Com^3.pptCom^3.ppt
Com^3.ppt
 
Opportunities and barriers in the biosimilar marketevolution or revolution fo...
Opportunities and barriers in the biosimilar marketevolution or revolution fo...Opportunities and barriers in the biosimilar marketevolution or revolution fo...
Opportunities and barriers in the biosimilar marketevolution or revolution fo...
 
GDHC118PIDR_Peripheral Artery Disease_sample
GDHC118PIDR_Peripheral Artery Disease_sampleGDHC118PIDR_Peripheral Artery Disease_sample
GDHC118PIDR_Peripheral Artery Disease_sample
 
Api china-2013
Api china-2013Api china-2013
Api china-2013
 
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
Shaping_the_biosimiliars_opportunity_A_global_perspective_on_the_evolving_bio...
 
2016-EDF-Pharma-Innovation
2016-EDF-Pharma-Innovation2016-EDF-Pharma-Innovation
2016-EDF-Pharma-Innovation
 
Patent cliff
Patent cliffPatent cliff
Patent cliff
 
Presentation Assogenerici_Biosimilars_Iervolino IMS
Presentation Assogenerici_Biosimilars_Iervolino IMSPresentation Assogenerici_Biosimilars_Iervolino IMS
Presentation Assogenerici_Biosimilars_Iervolino IMS
 
‘Orphan drugs’ future growth potential for indian pharmaceutical market
‘Orphan drugs’ future growth potential for indian pharmaceutical market‘Orphan drugs’ future growth potential for indian pharmaceutical market
‘Orphan drugs’ future growth potential for indian pharmaceutical market
 

Similar to What are the world's top selling drugs

FREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INCFREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
Bret Jensen
 
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...
Global Study Solutions - 9901366442
 
Global cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlookGlobal cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlook
KuicK Research
 
The Era Of Generics By Shaji July 2009
The Era Of Generics   By Shaji July 2009The Era Of Generics   By Shaji July 2009
The Era Of Generics By Shaji July 2009
shajanjohnvanilla
 
Targeted Cancer Therapies
Targeted Cancer TherapiesTargeted Cancer Therapies
Targeted Cancer Therapies
saprxl
 
Aggarwal Targeted Cancer Therapies Nature Reviews June 2010 Page One, contact...
Aggarwal Targeted Cancer Therapies Nature Reviews June 2010 Page One, contact...Aggarwal Targeted Cancer Therapies Nature Reviews June 2010 Page One, contact...
Aggarwal Targeted Cancer Therapies Nature Reviews June 2010 Page One, contact...
saurabhjhu
 
Niche buster drug
Niche buster drugNiche buster drug
Niche buster drug
Rhit Srivastava
 
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company
Debashish Kar
 
셀트리온 브로슈어 영 펼침면
셀트리온 브로슈어 영 펼침면셀트리온 브로슈어 영 펼침면
셀트리온 브로슈어 영 펼침면
celltrion
 
2016 Celltrion English
2016 Celltrion English2016 Celltrion English
2016 Celltrion English
celltrion
 
Adc drugs to be launched in 2020
Adc drugs to be launched in 2020Adc drugs to be launched in 2020
Adc drugs to be launched in 2020
DoriaFang
 
Shivai Gupta - POSTER
Shivai Gupta - POSTERShivai Gupta - POSTER
Shivai Gupta - POSTER
Shivai Gupta
 
Global cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlookGlobal cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlook
KuicK Research
 
Global cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlookGlobal cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlook
KuicK Research
 
How the biologics landscape is evolving
How the biologics landscape is evolvingHow the biologics landscape is evolving
How the biologics landscape is evolving
National Institute of Biologics
 
Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...
Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...
Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...
Eularis
 
AMGEN Financial Analysis
AMGEN Financial AnalysisAMGEN Financial Analysis
AMGEN Financial Analysis
Elizabeth Thompson
 
Emerging Trends In Pharma - HR Update
Emerging Trends In Pharma - HR UpdateEmerging Trends In Pharma - HR Update
Emerging Trends In Pharma - HR Update
Shibumi2009
 
Report on Gilead Sciences
Report on Gilead SciencesReport on Gilead Sciences
Report on Gilead Sciences
Randy Acosta
 
Genentech
GenentechGenentech

Similar to What are the world's top selling drugs (20)

FREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INCFREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
 
Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...Are there reasons for believing that the profitability of the industry might ...
Are there reasons for believing that the profitability of the industry might ...
 
Global cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlookGlobal cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlook
 
The Era Of Generics By Shaji July 2009
The Era Of Generics   By Shaji July 2009The Era Of Generics   By Shaji July 2009
The Era Of Generics By Shaji July 2009
 
Targeted Cancer Therapies
Targeted Cancer TherapiesTargeted Cancer Therapies
Targeted Cancer Therapies
 
Aggarwal Targeted Cancer Therapies Nature Reviews June 2010 Page One, contact...
Aggarwal Targeted Cancer Therapies Nature Reviews June 2010 Page One, contact...Aggarwal Targeted Cancer Therapies Nature Reviews June 2010 Page One, contact...
Aggarwal Targeted Cancer Therapies Nature Reviews June 2010 Page One, contact...
 
Niche buster drug
Niche buster drugNiche buster drug
Niche buster drug
 
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company
 
셀트리온 브로슈어 영 펼침면
셀트리온 브로슈어 영 펼침면셀트리온 브로슈어 영 펼침면
셀트리온 브로슈어 영 펼침면
 
2016 Celltrion English
2016 Celltrion English2016 Celltrion English
2016 Celltrion English
 
Adc drugs to be launched in 2020
Adc drugs to be launched in 2020Adc drugs to be launched in 2020
Adc drugs to be launched in 2020
 
Shivai Gupta - POSTER
Shivai Gupta - POSTERShivai Gupta - POSTER
Shivai Gupta - POSTER
 
Global cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlookGlobal cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlook
 
Global cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlookGlobal cancer biosimilars market opportunity outlook
Global cancer biosimilars market opportunity outlook
 
How the biologics landscape is evolving
How the biologics landscape is evolvingHow the biologics landscape is evolving
How the biologics landscape is evolving
 
Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...
Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...
Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...
 
AMGEN Financial Analysis
AMGEN Financial AnalysisAMGEN Financial Analysis
AMGEN Financial Analysis
 
Emerging Trends In Pharma - HR Update
Emerging Trends In Pharma - HR UpdateEmerging Trends In Pharma - HR Update
Emerging Trends In Pharma - HR Update
 
Report on Gilead Sciences
Report on Gilead SciencesReport on Gilead Sciences
Report on Gilead Sciences
 
Genentech
GenentechGenentech
Genentech
 

More from DoriaFang

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
DoriaFang
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
DoriaFang
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
DoriaFang
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
DoriaFang
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
DoriaFang
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
DoriaFang
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
DoriaFang
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
DoriaFang
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
DoriaFang
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
DoriaFang
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
DoriaFang
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DoriaFang
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
DoriaFang
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
DoriaFang
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
DoriaFang
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
DoriaFang
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
DoriaFang
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
DoriaFang
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
DoriaFang
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
DoriaFang
 

More from DoriaFang (20)

Cyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdfCyclic Peptides Current Status & Future Prospects.pdf
Cyclic Peptides Current Status & Future Prospects.pdf
 
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdfAntibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
Antibody–Oligonucleotide Conjugates (AOCs) in Clinical Trials.pdf
 
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdfAlzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
Alzheimer's Disease Drug Development Aducanumab, Lecanemab & Donanemab.pdf
 
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdfClaudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
Claudin6 (CLDN6) A Emerging Target For Solid Tumor.pdf
 
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdfROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
ROR1 ADCs in Clinical Trials MK-2140, NBE-002 & CS5001.pdf
 
Summary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdfSummary of Targeted Protein Degradation in Clinical Trials.pdf
Summary of Targeted Protein Degradation in Clinical Trials.pdf
 
Overview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdfOverview of New Targets For Anti-tumor Drugs.pdf
Overview of New Targets For Anti-tumor Drugs.pdf
 
Cleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdfCleavable Linkers Used In ADC Development.pdf
Cleavable Linkers Used In ADC Development.pdf
 
The Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdfThe Role of Four Lipid Components Of LNPs.pdf
The Role of Four Lipid Components Of LNPs.pdf
 
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdfTrophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
Trophoblast Glycoprotein (TPGB5T4) A New Target For ADC Drugs.pdf
 
Advances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdfAdvances in TROP-2 Directed ADCs.pdf
Advances in TROP-2 Directed ADCs.pdf
 
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdfDS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
DS-8201 (Enhertu) A Potential ADC Drug Targeting HER2.pdf
 
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdfList of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
List of New Anti-cancer Drugs Approved By FDA In The First Half of 2023.pdf
 
Overview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdfOverview of Oral Delivery Strategies for Peptides.pdf
Overview of Oral Delivery Strategies for Peptides.pdf
 
The Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdfThe Future Development of ADC For Cancer.pdf
The Future Development of ADC For Cancer.pdf
 
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdfSummary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
Summary of ADC Targets For Solid Tumors & Hematological Tumors.pdf
 
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdfNew Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
New Oncology Trends ADCs, Bispecific Antibodies & CAR-T Cell.pdf
 
Summary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdfSummary of Treatments for Multiple Myeloma.pdf
Summary of Treatments for Multiple Myeloma.pdf
 
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdfBispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
Bispecific Antibody-drug Conjugate Drugs In Clinical or Preclinical.pdf
 
ADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdfADCs Targeting the HER Family.pdf
ADCs Targeting the HER Family.pdf
 

Recently uploaded

Test Bank For Principles Of Cost Accounting, 17th Edition Edward J. Vander...
Test Bank For Principles Of Cost Accounting, 	  17th Edition Edward J. Vander...Test Bank For Principles Of Cost Accounting, 	  17th Edition Edward J. Vander...
Test Bank For Principles Of Cost Accounting, 17th Edition Edward J. Vander...
kevinkariuki227
 
Millionaire track government application
Millionaire track government applicationMillionaire track government application
Millionaire track government application
pragyasharma659549
 
Connected Small Boat Protection Solution | July 2024
Connected Small Boat Protection Solution | July  2024Connected Small Boat Protection Solution | July  2024
Connected Small Boat Protection Solution | July 2024
Hector Del Castillo, CPM, CPMM
 
Girls Call Andheri West 9910780858 Provide Best And Top Girl Service And No1 ...
Girls Call Andheri West 9910780858 Provide Best And Top Girl Service And No1 ...Girls Call Andheri West 9910780858 Provide Best And Top Girl Service And No1 ...
Girls Call Andheri West 9910780858 Provide Best And Top Girl Service And No1 ...
margaretblush
 
Gym business MODEL .pdf .
Gym business MODEL .pdf                 .Gym business MODEL .pdf                 .
Gym business MODEL .pdf .
Divyanshu56740
 
حبوب %77 الميفيبريستون 200 ملغ في دبي الامارات العين ابوظبي عجمان واتس - 0096...
حبوب %77 الميفيبريستون 200 ملغ في دبي الامارات العين ابوظبي عجمان واتس - 0096...حبوب %77 الميفيبريستون 200 ملغ في دبي الامارات العين ابوظبي عجمان واتس - 0096...
حبوب %77 الميفيبريستون 200 ملغ في دبي الامارات العين ابوظبي عجمان واتس - 0096...
حبوب الاجهاض سايتوتك للبيع في الامارات cytotec واتس 00966583759617
 
TALENT ACQUISITION AND MANAGEMENT LECTURE 5
TALENT ACQUISITION AND MANAGEMENT LECTURE 5TALENT ACQUISITION AND MANAGEMENT LECTURE 5
TALENT ACQUISITION AND MANAGEMENT LECTURE 5
projectseasy
 
9 Lessons From Jeff Bezos’ ONLY Podcast Appearance
9 Lessons From Jeff Bezos’ ONLY Podcast Appearance9 Lessons From Jeff Bezos’ ONLY Podcast Appearance
9 Lessons From Jeff Bezos’ ONLY Podcast Appearance
Levership
 
Patrick Dwyer Merrill Lynch - Founder of the Dwyer Family Foundation
Patrick Dwyer Merrill Lynch - Founder of the Dwyer Family FoundationPatrick Dwyer Merrill Lynch - Founder of the Dwyer Family Foundation
Patrick Dwyer Merrill Lynch - Founder of the Dwyer Family Foundation
Patrick Dwyer Merrill Lynch
 
You Get Me! Leveraging Communication Styles in Virtual Trainingpptx
You Get Me! Leveraging Communication Styles in Virtual TrainingpptxYou Get Me! Leveraging Communication Styles in Virtual Trainingpptx
You Get Me! Leveraging Communication Styles in Virtual Trainingpptx
Cynthia Clay
 
BBA Final SML 501 INTERNATIONAL BUSINESS .pdf
BBA Final SML 501 INTERNATIONAL BUSINESS .pdfBBA Final SML 501 INTERNATIONAL BUSINESS .pdf
BBA Final SML 501 INTERNATIONAL BUSINESS .pdf
mcdopex6
 
Don’t Get Left Behind: Leveraging Modern Product Management Across the Organi...
Don’t Get Left Behind: Leveraging Modern Product Management Across the Organi...Don’t Get Left Behind: Leveraging Modern Product Management Across the Organi...
Don’t Get Left Behind: Leveraging Modern Product Management Across the Organi...
Aggregage
 
TEST BANK For Auditing & Assurance Services A Systematic Approach, 12th Editi...
TEST BANK For Auditing & Assurance Services A Systematic Approach, 12th Editi...TEST BANK For Auditing & Assurance Services A Systematic Approach, 12th Editi...
TEST BANK For Auditing & Assurance Services A Systematic Approach, 12th Editi...
kevinkariuki227
 
MEA Union Budget 2024-25 Final Presentation
MEA Union Budget 2024-25 Final PresentationMEA Union Budget 2024-25 Final Presentation
MEA Union Budget 2024-25 Final Presentation
PhysicsUtu
 
Zodiac Signs and Fashion: Dressing to Suit Your Astrological Style
Zodiac Signs and Fashion: Dressing to Suit Your Astrological StyleZodiac Signs and Fashion: Dressing to Suit Your Astrological Style
Zodiac Signs and Fashion: Dressing to Suit Your Astrological Style
my Pandit
 
WAM Corporate Presentation July 2024.pdf
WAM Corporate Presentation July 2024.pdfWAM Corporate Presentation July 2024.pdf
WAM Corporate Presentation July 2024.pdf
Western Alaska Minerals Corp.
 
STRATEGY TO OVERCOME CURRENT PROBLEMS AT MTC.pptx
STRATEGY TO OVERCOME CURRENT PROBLEMS AT MTC.pptxSTRATEGY TO OVERCOME CURRENT PROBLEMS AT MTC.pptx
STRATEGY TO OVERCOME CURRENT PROBLEMS AT MTC.pptx
ImranTabish1
 
How to buy a fake Keiser University diploma
How to buy a fake Keiser University diplomaHow to buy a fake Keiser University diploma
How to buy a fake Keiser University diploma
College diploma
 
Luxury Lifestyle Summit 2024 - Sponsorship
Luxury Lifestyle Summit 2024 - SponsorshipLuxury Lifestyle Summit 2024 - Sponsorship
Luxury Lifestyle Summit 2024 - Sponsorship
uitdiedosfinance
 
New Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No1 in...
New Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No1 in...New Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No1 in...
New Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No1 in...
44annissa
 

Recently uploaded (20)

Test Bank For Principles Of Cost Accounting, 17th Edition Edward J. Vander...
Test Bank For Principles Of Cost Accounting, 	  17th Edition Edward J. Vander...Test Bank For Principles Of Cost Accounting, 	  17th Edition Edward J. Vander...
Test Bank For Principles Of Cost Accounting, 17th Edition Edward J. Vander...
 
Millionaire track government application
Millionaire track government applicationMillionaire track government application
Millionaire track government application
 
Connected Small Boat Protection Solution | July 2024
Connected Small Boat Protection Solution | July  2024Connected Small Boat Protection Solution | July  2024
Connected Small Boat Protection Solution | July 2024
 
Girls Call Andheri West 9910780858 Provide Best And Top Girl Service And No1 ...
Girls Call Andheri West 9910780858 Provide Best And Top Girl Service And No1 ...Girls Call Andheri West 9910780858 Provide Best And Top Girl Service And No1 ...
Girls Call Andheri West 9910780858 Provide Best And Top Girl Service And No1 ...
 
Gym business MODEL .pdf .
Gym business MODEL .pdf                 .Gym business MODEL .pdf                 .
Gym business MODEL .pdf .
 
حبوب %77 الميفيبريستون 200 ملغ في دبي الامارات العين ابوظبي عجمان واتس - 0096...
حبوب %77 الميفيبريستون 200 ملغ في دبي الامارات العين ابوظبي عجمان واتس - 0096...حبوب %77 الميفيبريستون 200 ملغ في دبي الامارات العين ابوظبي عجمان واتس - 0096...
حبوب %77 الميفيبريستون 200 ملغ في دبي الامارات العين ابوظبي عجمان واتس - 0096...
 
TALENT ACQUISITION AND MANAGEMENT LECTURE 5
TALENT ACQUISITION AND MANAGEMENT LECTURE 5TALENT ACQUISITION AND MANAGEMENT LECTURE 5
TALENT ACQUISITION AND MANAGEMENT LECTURE 5
 
9 Lessons From Jeff Bezos’ ONLY Podcast Appearance
9 Lessons From Jeff Bezos’ ONLY Podcast Appearance9 Lessons From Jeff Bezos’ ONLY Podcast Appearance
9 Lessons From Jeff Bezos’ ONLY Podcast Appearance
 
Patrick Dwyer Merrill Lynch - Founder of the Dwyer Family Foundation
Patrick Dwyer Merrill Lynch - Founder of the Dwyer Family FoundationPatrick Dwyer Merrill Lynch - Founder of the Dwyer Family Foundation
Patrick Dwyer Merrill Lynch - Founder of the Dwyer Family Foundation
 
You Get Me! Leveraging Communication Styles in Virtual Trainingpptx
You Get Me! Leveraging Communication Styles in Virtual TrainingpptxYou Get Me! Leveraging Communication Styles in Virtual Trainingpptx
You Get Me! Leveraging Communication Styles in Virtual Trainingpptx
 
BBA Final SML 501 INTERNATIONAL BUSINESS .pdf
BBA Final SML 501 INTERNATIONAL BUSINESS .pdfBBA Final SML 501 INTERNATIONAL BUSINESS .pdf
BBA Final SML 501 INTERNATIONAL BUSINESS .pdf
 
Don’t Get Left Behind: Leveraging Modern Product Management Across the Organi...
Don’t Get Left Behind: Leveraging Modern Product Management Across the Organi...Don’t Get Left Behind: Leveraging Modern Product Management Across the Organi...
Don’t Get Left Behind: Leveraging Modern Product Management Across the Organi...
 
TEST BANK For Auditing & Assurance Services A Systematic Approach, 12th Editi...
TEST BANK For Auditing & Assurance Services A Systematic Approach, 12th Editi...TEST BANK For Auditing & Assurance Services A Systematic Approach, 12th Editi...
TEST BANK For Auditing & Assurance Services A Systematic Approach, 12th Editi...
 
MEA Union Budget 2024-25 Final Presentation
MEA Union Budget 2024-25 Final PresentationMEA Union Budget 2024-25 Final Presentation
MEA Union Budget 2024-25 Final Presentation
 
Zodiac Signs and Fashion: Dressing to Suit Your Astrological Style
Zodiac Signs and Fashion: Dressing to Suit Your Astrological StyleZodiac Signs and Fashion: Dressing to Suit Your Astrological Style
Zodiac Signs and Fashion: Dressing to Suit Your Astrological Style
 
WAM Corporate Presentation July 2024.pdf
WAM Corporate Presentation July 2024.pdfWAM Corporate Presentation July 2024.pdf
WAM Corporate Presentation July 2024.pdf
 
STRATEGY TO OVERCOME CURRENT PROBLEMS AT MTC.pptx
STRATEGY TO OVERCOME CURRENT PROBLEMS AT MTC.pptxSTRATEGY TO OVERCOME CURRENT PROBLEMS AT MTC.pptx
STRATEGY TO OVERCOME CURRENT PROBLEMS AT MTC.pptx
 
How to buy a fake Keiser University diploma
How to buy a fake Keiser University diplomaHow to buy a fake Keiser University diploma
How to buy a fake Keiser University diploma
 
Luxury Lifestyle Summit 2024 - Sponsorship
Luxury Lifestyle Summit 2024 - SponsorshipLuxury Lifestyle Summit 2024 - Sponsorship
Luxury Lifestyle Summit 2024 - Sponsorship
 
New Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No1 in...
New Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No1 in...New Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No1 in...
New Girls Call Mumbai 9910780858 Provide Best And Top Girl Service And No1 in...
 

What are the world's top selling drugs

  • 1. Huateng Pharma https://en.huatengsci.com What Are The World's Top Selling Drugs? After reviewing the top 10 oncology pharmaceutical companies 2020, now let's find the top 10 best-selling drugs in the world of 2020. Top 10 Best-selling Drugs of 2020  1. Humira (AbbVie) — $20.39 billion  2. Keytruda (Merck & Co.) — $14.38 billion  3. Revlimid (Bristol Myers Squibb) — $12.15 billion  4. Eliquis (Bristol Myers Squibb and Pfizer ) — $9.17 billion  5. Imbruvica (AbbVie, Johnson & Johnson) — $8.43 billion  6. Eylea (Regeneron Pharmaceuticals, Bayer) — $8.36 billion  7. Stelara (Janssen )—$7.94 billion  8. Opdivo (Bristol Myers Squibb, Ono Pharmaceutical) — $7.92 billion  9. Biktarvy (Gilead) —$7.26 billion  ​ 10. Xarelto (Bayer ) — $6.93 billion ​
  • 2. Huateng Pharma https://en.huatengsci.com 1. Humira (Adalimumab) Company: AbbVie Mechanism of action: TNFα inhibitor Approved indications: rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, ulcerative colitis, plaque psoriasis Sales in 2020: $20.39 billion Adalimumab has a 3.5% global growth in 2020 after experiencing a decline in sales of up to 3.9% in 2019. Adalimumab faced competition from European biosimilars for the first time in 2019, when its international sales declined by up to 31%. However, during the COVID-19 epidemic in 2020, adalimumab sales increased every quarter, from $4.77 billion in the first quarter to $5.15 billion in the fourth quarter, due to the inconvenience of patients visiting hospitals and the tendency to maintain their original treatment. Adalimumab will remain at the head of the immune field for the next few years, with its biggest rival being Johnson & Johnson's Stelara, which generated sales of $7.71 billion last year. The U.S. biosimilar market is also seeing increased competition as adalimumab's patent expiration date approaches in 2023. Adalimumab has remained the world's best-selling drug since 2012, and if it remains at the top in 2021, it will surpass Lipitor as the world's best-selling drug of all time. 2. Keytruda (Pembrolizumab) Company: Merck & Co. Mechanism of action: PD-1 blocker Approved indications: melanoma, non-small cell lung cancer, small cell lung cancer, head and neck cancer, Hodgkin lymphoma, large B-cell lymphoma, bladder cancer, colorectal cancer, stomach cancer, esophageal cancer, cervical cancer, liver cancer, Merkel cell carcinoma, kidney cancer (in combination with Inlyta), endometrial cancer (in combination with Lenvima) Sales in 2020: $14.38 billion Merck seized the opportunity when immune targets became a direction of treatment for cancer. Keytruda could claim the top spot by 2023 when AbbVie’s Humira patent expires.
  • 3. Huateng Pharma https://en.huatengsci.com The immuno-oncology market is changing rapidly. Sales of Opdivo, also a PD-1 inhibitor, have been declining, while Keytruda has received seven FDA approvals in the past 10 months. Keytruda is an important advance in the treatment of advanced cancers with a large number of genetic mutations, often in children with TMB-H cancers that are difficult to cure. Keytruda has also received approval for relapsed or metastatic squamous cell carcinoma of the skin that cannot be cured by surgery or radiation therapy, and for the first-line treatment of patients with metastatic or inoperable colorectal cancer with high microsatellite instability or mismatch repair defects. Keytruda is also approved for the treatment of Hodgkin's lymphoma and breast cancer, as well as an approval last month for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction cancer. Merck continues its efforts to extend the drug's patent life through co-formulations, combinations and alternate routes of administration. 3. Revlimid(Lenalidomide) Company: Bristol Myers Squibb Mechanism of action: IL6 inhibitor; CRBN inhibitor; COX-2 inhibitor; TNFα inhibitor Approved indications: Multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma Sales in 2020: $12.15 billion Revlimid, approved by the FDA in 2005, had a down period after being acquired in 2019, but last year it reached sales of more than $12 billion, jumping to the top three drugs by annual sales. This was achieved with multiple price increases for Revlimid. Celgene sold the drug initially for $215, but after 20 price increases, it now costs more than $750. Celgene used these aggressive price increases to reach its financial goals. Both Celgene and BMS struggled to keep Revlimid safe from generic competition. Shortly after the acquisition was completed, the U.S. Patent and Trademark Office denied Revlimid's application to invalidate three patents. Last year, however, BMS made concessions to allow Indian generic drug makers to produce a limited number of generics after March 2022, and the three drugmakers mentioned in the agreement signed by BMS can launch an unlimited number of generics in 2026. BMS was willing to free up the market for Revlimid generics as they had just received two CAR-T approvals and they were in the early stages of the key
  • 4. Huateng Pharma https://en.huatengsci.com launch phases for anemia, multiple sclerosis and acute myeloid leukemia. BMS was confident of future gains. 4. Eliquis (Apixaban) Company: Bristol Myers Squibb and Pfizer Mechanism of action: inhibitor of free and clot-bound factor Xa Approved indications: Nonvalvular atrial fibrillation Sales in 2020: $9.17 billion Eliquis, jointly developed by Pfizer and BMS, was approved by the EMA in 2011 and by the FDA in 2012. Eliquis ranks as the fifth best-selling drug in the world with annual sales of more than $9 billion in 2020. Pfizer funds around half of the development costs, and the two companies share profits and losses equally. In some countries, Pfizer sells the drug and pays BMS a fee. Pfizer and BMS have changed dramatically in recent years as Eliquis sales have soared. Pfizer moved both its generic and off-patent Upjohn businesses to focus more on innovation and new drugs, and BMS acquired Celgene. Prescriptions for oral anticoagulants show an overall downward trend during the COVID-19 epidemic in 2020, with a rebound in volume by early 2021. Eliquis sales jumped 37% to $2.6 billion in the first quarter as related studies showed that blood thinners can boost the efficacy of COVID-19. Eliquis sales increased 16% over 2019. Pfizer earned a total of $4.95 billion in joint revenue with BMS and direct sales. The outlook for Eliquis is good as the market expands further. 5. Imbruvica (Ibrutinib) Company: AbbVie, Johnson & Johnson Mechanism of action: BTK inhibitor Approved indications: Mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia, marginal zone lymphoma, chronic graft vs. host disease Sales in 2020: $8.43 billion Imbruvica is now one of the world's leading anti-blood cancer drugs, with sales reaching $8.43 billion last year, demonstrating its dominance in the BTK inhibitor market.
  • 5. Huateng Pharma https://en.huatengsci.com Imbruvica's 2020 sales are split between AbbVie ($5.31 billion) and Johnson & Johnson ($4.13 billion). AbbVie's revenue includes $1.09 billion in collaboration revenue. Johnson & Johnson acquired 50% of Imbruvica for less than $1 billion in 2011, and four years later Imbruvica's price skyrocketed due to AbbVie's $21 billion acquisition of Pharmacyclics and a lone product. A year later, Imbruvica received key approval as the first chemotherapy-free treatment for first-line chronic lymphocytic leukemia patients. Since then, the therapy has received six more approvals, the last three in combination with other drugs. But like other drugs, Imbruvica faces challengers. The first is AstraZeneca's Calquence, approved by the FDA in November 2019, with long-term data published last year showing that treated patients with cytosolic lymphoma had an average disease duration of 22 months without progression and a survival rate of more than 50% after three years. Another competitor is Brukinsa from BeiGene, which is only approved in the US for condyloma lymphoma. The drug won the nod in China for recurrent SLL / CLL. Late last year, BeiGene showed that for marginal zone lymphoma, Brukinsa elicited responses in 74% of patients and completely eliminated the cancer in 24% within a year. The corresponding figures for Imbruvika were 48% and 5%, respectively, although the trials did not compare the two drugs with each other. To keep Imbruvica sales growing, AbbVie built a strong patent wall around it, extending its exclusivity patent period by nine years, shielding it from biosimilar competition and thus allowing prices to remain high and bring in more revenue. 6. Eylea (Aflibercept ) Company: Regeneron Pharmaceuticals, Bayer Mechanism of action: PGF inhibitor, VEGFA inhibitor Approved indications: wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema Sales in 2020: $8.36 billion Eylea booked $8.36 billion in 2020 sales, split between $4.95 billion for Regeneron in the U.S., and $2.82 billion for Bayer, which markets the macular degeneration drug outside the U.S. Due to the COVID-19 outbreak, new patients only got access to Eylea in late March and early April, but the drug still performed better in the first quarter than most of the year. In the second quarter, Eylea sales declined 4 percent but still exceeded expectations, and by the fourth quarter, Eylea sales were up 10 percent and full-year sales were up 7 percent over 2019.
  • 6. Huateng Pharma https://en.huatengsci.com Eylea's competitor is Novartis' Beovu, however, last year it was reported that Beovu may be linked to obstructive retinal vasculitis, which may lead to vision loss. Regeneron and Bayer used this to promote Eylea's drug safety. In April 2020, the National Institutes of Health released data showing that Eylea reduces the risk of developing vision-threatening complications by 68 percent. But in the middle of last year, Novartis filed a lawsuit against Regeneron for infringement of the pre-filled syringe technology, setting off an all-out patent battle between Regeneron and Novartis in the ophthalmology field. 7. Stelara(Ustekinumab) Company: Janssen Mechanism of action: IL12 inhibitor, IL23 inhibitor Approved indications: plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis Sales in 2020: $7.94 billion Stelara's approval in ulcerative colitis has a strong impact on its sales growth in 2020. Meanwhile, the FDA's safety warning for Stelara's two JAK inhibitor competitors (Xeljanz and Rinvoq) has also helped its market share capture. Johnson & Johnson has cut the price of its IL-12 / 23 significantly to remain competitive in light of growing competition. Despite this, Stelara achieved $7.94 billion in revenue last year, an increase of nearly 20% over 2019. But Stelara also faces threats from the price side. One is from competing drugs, and after Johnson & Johnson reported third-quarter results, it is considering discounting and reducing prices on its products to secure market share. The second is from government controls on drug prices, combined with high unemployment and other effects, and price pressure could continue into 2021. 8. Opdivo (Nivolumab) Company: Bristol Myers Squibb, Ono Pharmaceutical Mechanism of action: PD-1 inhibitor Approved indications: melanoma, non-small cell lung cancer, small cell lung cancer, kidney cancer, Hodgkin Lymphoma, head and neck cancer, bladder cancer, colorectal cancer, liver cancer Sales in 2020: $7.92 billion In terms of biopharmaceutical competition, a familiar fight is believed to be the Keytruda-Opdivo battle, which is akin to Pepsi and Coke.
  • 7. Huateng Pharma https://en.huatengsci.com During the development process, they competed with each other as immune checkpoint inhibitor rivals, and were approved by FDA successively in the same year. Early on, Opdivo was in the lead, but later on, the development was quite opposite. Keytruda sales grew 29% in 2020, while Opdivo's share continued to shrink as Keytruda's market share continued to grow, but Opdivo's declined 2%. And in each quarter of 2020 and the last quarter of 2019, Opdivo sales declined compared to the same period last year. Keytruda received 7 FDA approvals in 2019, but no gains for Opdivo. In non-squamous non-small cell lung cancer, the combination therapy of Opdivo with chemotherapy also did not show a significant improvement in efficacy over chemotherapy alone. But in 2020, Opdivo has received seven FDA approvals, two of which were in combination with Bristol's CTLA4 immunotherapy Yervoy, for use in key NSCLC areas. There have also been recent positive evaluations for gastric and esophageal cancers. In addition, last October, Opdivo reported another NSCLC win - a positive effect of Opdivo in combination with chemotherapy prior to surgery, with Opdivo beating several competitors, including its dreaded nemesis. Opdivo was first shown to be effective in treating muscle-invasive bladder cancer in a clinical trial in February of this year. This was followed by another clinical success in April - patients with early-stage non-small cell lung cancer who were treated with a combination of Opdivo and chemotherapy prior to surgery were nearly 14 times more likely to have cancer-free tissue in their resected tissue than patients treated with chemotherapy alone. This is a milestone in the yet-to-be-realized adoption of Keytuda. The competition among PD-1 inhibitors is being rekindled. 9. Biktarvy Company: Gilead Sciences Mechanism of action: HIV integrase inhibitor; RT inhibitor; HIV-1 RT inhibitor Approved indications: HIV Sales in 2020: $7.26 billion Compared to 2019, Biktarvy's 2020 sales increase by 53%, jumping from the 17th to the 9th best-selling drug, far exceeding the original projected goal. Although Biktarvy sales jumped $2.52 billion in 2020, a large portion of patients using Biktarvy were originally using Gilead's other anti-HIV products, which had a $1.93 billion sales decline. Overall, Gilead's HIV products generated sales of $16.94 billion in 2020. Although this figure represents 69 percent of the
  • 8. Huateng Pharma https://en.huatengsci.com company's total revenue, Gilead's HIV drug revenue is up just 3 percent from 2019. Biktarvy's competition doesn't just come from the inside of the company, such as Descovy, which saw its sales in the U.S. jump from $1.08 billion in 2019 to $1.53 billion last year. Competition from outside the company is equally strong. GSK has been in the HIV space for two decades, and its joint venture with Pfizer and Shionogi, ViiV Healthcare, introduces strong challengers to the market every few years. ViiV is pinning its latest hopes on Dovato, a two-drug combination with a better safety profile that generated $374 million in sales in its first year of approval in 2019. 10. Xarelto (Rivaroxaban) Company: Bayer Mechanism of action: inhibitor of free and clot-bound factor Xa Approved indications: Pulmonary embolism; Stroke; Venous thrombosis; Embolism; Venous thromboembolism; Arterial atherosclerosis Sales in 2020: $6.93 billion In 2020, Xarelto's total revenue was about $6.93 billion, slightly more than its $6.35 billion in 2019. Bayer received $4.58 billion of that amount, while Johnson & Johnson received about $2.35 billion. 9% sales growth was not enough to gain an edge against Pfizer and BMS' Eliquis, which had full-year sales of about $9.17 billion, and Eliquis continues to dominate the blood thinner segment. The FDA approved Xarelto in October 2019 to help prevent blood clots in acutely ill patients and without a high risk of bleeding during and after hospitalization.The FDA's nod marks the sixth indication for Xarelto for blood clots, while Eliquis is for the third indication. Last March, the American College of Medicine (ACM) released data showing that the combination of Xarelto and aspirin resulted in a 15% reduction in the risk of major limb and cardiovascular events in patients with symptomatic peripheral arterial disease. Reference: https://www.fiercepharma.com/special-report/top-20-drugs-by-2020-sales As a reliable pharmaceutical intermediates supplier, Huateng Pharma is able to provide the services of pharma intermediates's process development and scale-up production with capacities varying from gram to kilograms and multi tons. We have our own industrial park of 34,000 square meters that has been completed and put into operation since 2020 to support multi tons production.
  • 9. Huateng Pharma https://en.huatengsci.com Related Articles: The Rise of Antibody-Drug Conjugates (ADCs) - 'Guided-Missile' Cancer Drugs New Drug Approvals & Upcoming FDA Approvals 2021 ​ Top 8 Blockbuster Peptide Drugs ​ Top 10 Oncology Pharmaceutical Companies 2020​